CNX THERAPEUTICS LIMITED

1. CNX THERAPEUTICS LIMITED 2021-08-23 → present
2. SUNOVION PHARMACEUTICALS EUROPE LTD. 2013-10-09 → 2021-08-23
3. SUNOVION PHARMACEUTICALS EUROPE LTD 2013-04-02 → 2013-04-02
4. DAINIPPON SUMITOMO PHARMA EUROPE LTD. 2006-04-03 → 2013-04-02
5. SUMITOMO PHARMACEUTICALS EUROPE LIMITED 2001-10-01 → 2006-04-03
6. SUMITOMO PHARMACEUTICALS UK LIMITED 1997-05-01 → 2001-10-01

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company's Investors have provided a letter of support which guarantees that any future funds required to continue as a going concern if necessary for a period of no less than 12 months from the date these financial statements are approved. ... After making enquiries, including taking into account the Company and Group's forecasts, the Directors consider it appropriate to prepare these financial statements on a going concern basis.”

Group structure

1. CNX THERAPEUTICS LIMITED · parent
   1. CNX Therapeutics Netherlands B.V. 100% · Netherlands · Holding company
   2. Solar UK OPCO Limited 100% · United Kingdom · Holding company
   3. CNX Therapeutics Ireland Limited 100% · Ireland · Trading company
   4. CNX Therapeutics France S.A.S 100% · France · Trading company

Significant events

• “The above expansion was facilitated by a new loan arrangement with Ares Management Limited which was drawn by Solar BidCo Limited, one of the Company's parent entities. This loan was partially drawn down in the year to fund the Polar acquisition that closed in March 2024. Further funding is available to support the Company and Group's future strategy.”
• “The company now has a new ultimate parent company and is now part of a new group effective 22 May 2025. Under the new group, the ultimate parent undertaking is Clementine Topco Ltd, a company incorporated in Guernsey. The registered address is Px Box 286, Floor 2, Trafalgar Court, Les Banques, St Peter Port, Guernsey.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +40.3%

  £26,757,353 → £37,539,791

• Cash

  -72.2%

  £6,903,521 → £1,921,427

• Net assets

  -20,819.4%

  £43,228 → -£8,956,569

• Employees

  +59.3%

  27 → 43

• Operating profit

  -64.1%

  £3,631,389 → £1,305,239

• Profit before tax

  -237.4%

  -£3,671,581 → -£12,389,525

• Wages

  +83.4%

  £2,382,979 → £4,371,442

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers